Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.40 |
| ▸ | PTGIR | P43119 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | ACACA | Q13085 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17444434 | 0.93 | CNR2 (0.36) | CNR2PTGIRACACBACACAMEN1 | |
| SCHEMBL17444433 | 0.93 | CNR2 (0.36) | CNR2PTGIRACACBACACAMEN1 | |
| SCHEMBL25284961 | 0.92 | MEN1 (0.42) | CNR2PTGIRACACBACACAMEN1 | |
| SCHEMBL19267841 | 0.92 | MEN1 (0.46) | CNR2ACACBACACAMEN1MAPT | |
| SCHEMBL1428636 | 0.88 | CHRM3 (0.46) | HDAC3HDAC1HDAC2CHRM2CHRM1 | |
| SCHEMBL3603129 | 0.83 | GBA1 (0.33) | ACACBACACAMEN1MAPTKMT2A | |
| SCHEMBL1367746 | 0.83 | HDAC1 (0.38) | ACACBACACAMEN1MAPTKMT2A | |
| SCHEMBL24700932 | 0.83 | HDAC3 (0.38) | ACACBACACAMEN1MAPTKMT2A | |
| SCHEMBL25274161 | 0.82 | CHRM3 (0.42) | MEN1MAPTKMT2AATMHDAC3 | |
| Hydrochloric Acid SCHEMBL22291356 | 0.82 | HDAC1 (0.38) | ACACBACACAMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102378757-A | Pyrimidine compounds | ASTELLAS PHARMA INC | 2012-03-14 | — | — | CN | claimed |
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| CN-106257976-A | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2016-12-28 | — | — | CN | disclosed |
| CN-104114553-A | Substituted pyrazolo[1,5-a] pyridine as tropomyosin receptor kinase (Trk) inhibitors | REDDYS LAB LTD DR | 2014-10-22 | — | — | CN | disclosed |
| CN-102762208-A | Pyrazolopyrimidines and related heterocycles as ck2 inhibitors | CYLENE PHARMACEUTICALS INC | 2012-10-31 | — | — | CN | disclosed |
| CN-102625803-A | Pharmaceutically useful heterocycle-substituted lactams | CYLENE PHARMACEUTICALS INC | 2012-08-01 | — | — | CN | disclosed |
| CN-102378757-A | Pyrimidine compounds | ASTELLAS PHARMA INC | 2012-03-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | RAD51, FANCI, BLM | CNR2 4343/4885PTGIR 2666/4885ACACB 4205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.